Trial Profile
Phase 1 Study of EGFRvIII-Directed CAR T Cells Combined With PD-1 Inhibition in Patients With Newly Diagnosed, MGMT-Unmethylated Glioblastoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2023
Price :
$35
*
At a glance
- Drugs Anti-EGFRvIII CAR T cells (Primary) ; Pembrolizumab (Primary)
- Indications Astrocytoma; Glioblastoma
- Focus Adverse reactions
- 23 Sep 2023 Results assessing safety and tolerability of CART-EGFR vIII cells administered concomitantly with pembrolizumab in patients with newly diagnosed glioblastoma, presented at the CRI-ENCI-AACR: 7th Annual International Cancer, Immunotherapy Conference.
- 02 Mar 2021 Status changed from active, no longer recruiting to completed.
- 18 Jan 2021 Time frame for primary endpoint changed from 5 months to 15 years